Webinar

bluebird bio And Lonza Reflect On Their 10-Year Journey Commercializing Two Gene Therapies

Source: Lonza

As the lead partner for CAR-TCR 2023, we were thrilled to deliver the opening plenary session, delving into "The CDMO Value Proposition of Experience for Your Autologous Cell Therapy." This panel session features a decade-long story of partnership in bringing two life-changing gene therapies to market successfully in 2022.

Speakers:

Kelly Kral, VP, CMC Strategy & Operations, bluebird bio
Anthony Basile, Account Management CGT, Lonza

access the Webinar!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Lonza